• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Method of obtaining amorphous calcium phosphate nanoparticles coated with citrate and doped with fluorine. This material presents applications in biomedicine due to its excellent biodegradability and bioactivity; it also promotes cell adhesion and osteogeneration. In dentistry, it can be used in toothpastes, mouth rinses, chewing gum, gels and fluorine varnishes as a remineralizing agent of dentin and enamel. Part of two solutions formed by calcium chloride and sodium citrate on the one hand, and sodium monohydrogen phosphate and sodium carbonate with a fluorine compound, which are mixed at room temperature. The procedure is eco-efficient as it does not leave any acid residue; it consists of a single stage and is the first time that an amorphous calcium phosphate coated with citrate and doped with fluorine is obtained which enhances its remineralizing action. (Machine-translation by Google Translate, not legally binding)
    公开号:ES2557183A1
    申请号:ES201431091
    申请日:2014-07-21
    公开日:2016-01-22
    发明作者:José Manuel DELGADO LÓPEZ；Jaime GÓMEZ MORALES；Raquel FERNÁNDEZ PENAS；Michele Iafisco；Anna Tampieri；Silvia PANSERI
    申请人:Consejo Superior de Investigaciones Cientificas CSIC；Consiglio Nazionale delle Richerche CNR；
    IPC主号:
    专利说明:

    5
    10
    fifteen
    twenty
    25
    30
    35
    40
    Four. Five
    fifty
    Procedure for obtaining amorphous calcium phosphate nanoparticles coated with citrate and fluorinated.
    SECTOR AND OBJECT OF THE INVENTION
    Biomateriaies of interest in biomedicine (drug transporter and bone regeneration) and dentistry.
    The object of the invention is a process for obtaining amorphous calcium phosphate nanoparticles coated with citrate (a molecule that is part of the organic phase of the bone) and doped with fluoride. This material has a wide range of applications in the field of biomedicine (drug transporter and bone regeneration) due to its excellent biodegradability and bioactivity, in addition to promoting cell adhesion and osteogeneration. It also has multiple applications in dentistry where it can be used in toothpastes, mouthwashes, fluoride varnishes, chewing gum and gels as a remineralizing agent for dentin and enamel.
    The process starts from two solutions formed by calcium chloride and sodium citrate on the one hand, and by sodium monohydrogen phosphate and sodium carbonate with a fluorine compound, which are mixed at room temperature. It has the advantages, compared to the prior art, that the process is eco-efficient since it does not leave any acidic residue (strong acids are not used in the synthesis), of being synthesized in a single stage (when using sodium citrate as a reagent in the synthesis) and if it is the first time that an amorphous calcium phosphate coated with citrate and doped with fluoride is obtained, therefore with a more potent remineralizing action than amorphous calcium phosphate.
    STATE OF THE TECHNIQUE
    The amorphous phase is a rare way of finding calcium calcium phosphate (CaP) mineral in living organisms. Amorphous calcium phosphate (ACP) has been found in the mitochondria of eukaryotic and prokaryotic cells and is considered the precursor phase in the process of formation of the mineral phase of the bone, nanocrystalline carbonate-apatite, whose surface has recently been found to be It is covered with citrate. The ACP also acts as an intermediate phase in the preparation of various CaP through different methods. This material has a wide range of applications in the field of biomedicine due to its interesting properties such as excellent bioactivity, facilitates cell adhesion, easy biodegradation and also favors osteoconductivity and osteogeneration. It also has multiple applications in dentistry where it can be used in toothpastes, mouthwashes, chewing gum, gels and varnishes as a remineralizing agent for dentin and enamel. Fluoride varnishes are currently the most commonly used remineralizing products by dentists in Europe.
    WO98 / 40406 is known to be a product that is composed of amorphous calcium phosphate stabilized with caselna, a phosphoprotene present in milk. This product is currently being used as an abrasive material in toothpastes, chewing gums and in tooth whitening post-treatments. However, its effectiveness in preventing tooth decay and remineralizing damaged enamel has not yet been proven. ACP is also being used in composite polymeric materials as a filling material for the repair of dental pieces. The ACP stimulates the repair of the tooth because especially the acidic pHs generated by the bacterial plate produces the release of Ca and phosphate ions that are deposited on the tooth structure as hydroxyapatite regenerating the enamel
    5
    10
    fifteen
    twenty
    25
    30
    35
    (mainly composed of crystalline hydroxyapatite). Table 1 summarizes the main applications of ACP as a biomaterial.
    Table 1. Amorphous calcium phosphates used as biomaterials.
     Type of material  Effect Application
     Cements  Bone replacement Odontologla Curing agent Absorbable with great surface reactivity. Source of ions Ca2 + and PO43 "
     Coatings  Metallic prosthesis Increases biodegradability and its biological activity
     Mineral / organic compounds  Remineralization of teeth Bone replacement Improves its mechanical properties Release of Ca2 + and PO43 ions - increasing its biological activity
     Aqueous suspension  Gene liberation Absorbable and biocompatible. PH dependent stability
    Some of these applications have been compiled in J. Zhao et al. Amorphous calcium phosphate and its application in dentistry; Chemistry Central Journal (2011), 5:40 (doi: 10.1186 / 1752-153X-5-40).
    As for the preparation of ACP, it is known in various modalities starting from soluble precursors of Ca2 + and PO43- at suitable pHs for precipitation, being common the use of soluble precursors whose cation does not lead to other species that could interfere later in the composition of the final product, such as Ca (OH) 2, H3PO4, phosphate or ammonium hydrogen phosphate. Ca (NO3) 2 is frequently used 2.
    The function of the citric acid as a complexing agent of the Ca2 + cation is also known, which is also pharmaceutically acceptable, as are, for example, other polycarboxylic acids such as tartaric acid. For this reason these acids are also used to stabilize amorphous ACP compositions. This is set out in the claims of publication WO03059304 where the citric acid is proposed, among other chelating agents with the Ca2 + cation, in a proportion of 0.1% to 5% by weight in a preparation containing ACP combined with a phosphopeptide .
    In JP2001169121, the use of citric acid as a stabilizer of ACP already formed by precipitation from phosphoric acid and calcium hydroxide is proposed, subjecting the assembly to a subsequent milling in the presence of the referred citric acid.
    Therefore, none of these publications mentions a preparation such as that of the process object of the present invention, in which citrate is provided as a reagent for the precipitation of ACP (process in one stage) and not as a stabilizer in a phase after the precipitation (two-stage process).
    In the reviews of Dorozhkin S. V. [Nanosized and nanocrystalline calcium orthophsphates, Acta Biomaterialia (2010), No. 6 (3), 715-734]; Combes C. and Rey C. [Amorphous calcium phosphates: synthesis, properties and uses in biomaterials, Acta Biomaterialia (2010), No.6 (9), 3362-3378] and another review of Dorozhkin SV [Amorphous calcium phosphates, Acta Biomaterialia (2010), No.6 (12), 4457-4475 various procedures are collected via
    5
    10
    fifteen
    twenty
    25
    30
    35
    40
    Four. Five
    fifty
    wet, but in which the same conditions, process steps and reagents as in the process object of the present invention do not apply. In fact, citric acid is contemplated numerous times as a dispersing agent in these preparations and occasionally carbonate anion with similar functions.
    The publication of J.M. Delgado-Lopez et al. Crystallization of bioinspired citrate-functionalized nanoapatite with tailored carbonate content (Acta Biomaterialia (2012) No.8, p. 3491) establishes a procedure for precipitating apatite and nanocrystalline carbonate-apatite coated with citrate. The substantial differences in the state of the art between the procedure object of the present invention and this document are:
    (1) Precipitation temperature
    (2) Precipitation of ACP nanoparticles doped with fluorine and coated with citrate as a stable phase.
    (3) There is no process of maturation of the precipitate
    (4) Apatite or any other crystalline phase of calcium phosphate is not formed in the precipitate. BRIEF DESCRIPTION OF THE INVENTION
    A first object of the present invention is a method for obtaining amorphous calcium-coated calcium phosphate nanoparticles (FACP) comprising:
    - preparation of a solution of CaCl2 at a concentration between 0.08 M and 0.12 M and Na3C6H5O7 (sodium citrate) at a concentration between 0.35 M and 0.50 M.
    - Preparation of a second solution formed by Na2HPO4 at a concentration between 0.10 M and 0.15 M with 0.2 M Na2CO3 and a fluorine compound.
    - mixing under agitation of the two solutions prepared in the previous stages in proportion 1: 1 v / va pH between 8.3 and 8.7 (adjusted for example with HCl) and at room temperature for a period of time less than 2 minutes .
    - three successive cycles of sedimentation by centrifugation, elimination of the supernatant and washing of the precipitate with ultrapure water.
    - freeze drying of the wet precipitate.
    In a preferred embodiment of the invention, the concentrations of the reagents used for the first solution are 0.1 M for CaCl 2 and 0.4 M for Na 3 C 6 H 5 O 7 and the concentrations used for the second solution are 0.12 M for Na2HPO4 and 0.2 M for Na2CO3.
    The fluorine compound is selected from CaF2, NaF or KF and added at a concentration between 0.01 M and 0.1 M. In a preferred embodiment, the fluorine compound is CaF2 and added to a concentration of 0.05 M.
    It is another object of the present invention amorphous calcium fluorinated calcium phosphate nanoparticles, obtained by the above procedure, which have a spherical shape and size between 30 and 80 nm, as! as the following contents of Na, Ca, P, citrate, carbonate, fluoride and structural water:
    - between 3.1 and 3.5% by weight of Na
    - between 27.0 and 27.4% by weight of Ca
    - between 37.0 and 37.8% by weight of P
    - between 3.5 and 5.0% by weight of citrate
    - between 5.4 and 7.0% by weight of carbonate
    - between 6 and 10% by weight of water
    5
    10
    fifteen
    twenty
    25
    30
    35
    40
    Four. Five
    fifty
    - between 2 and 5% by weight of fluoride
    The term "water" refers in this aspect of the present invention to both adsorbed water and structural water.
    In a third aspect, it is another object of the present invention to use nanoparticles in applications such as:
    - transport of biomolecules and / or drugs
    - biomaterials in orthopedic applications
    - in dentistry, preferably as a material to prepare cements for filling and / or sealing in root canals and dental repairs, or as a component of toothpastes, chewing gums, mouthwashes, fluoride varnishes and gels to favor the remineralization of enamel by gradual release of calcium, phosphate and fluorine ions.
    BRIEF DESCRIPTION OF THE FIGURES
    Figure 1: Images of transmission electron microscopy (TEM) of the nanoparticles of ACP (a) and FACP (b) coated with citrate. The electron diffraction patterns obtained for each of the nanoparticles are also shown. In panels c and d, the X-ray energy dispersion spectra (EDS) of ACP and FACP, respectively, are shown.
    Figure 2. X-ray diffractograms (a) and Raman spectra (b) of the nanoparticles.
    Figure 3. Cell proliferation assays by MTT of human osteoblasts incubated for 1, 3 and 7 days with ACP nanoparticles (100 pg / mL, 500 pg / mL, 1000 pg / mL). * p <0:05; *** p <0: 001; n = 3.
    MODE OF EMBODIMENT OF THE INVENTION
    ACP nanoparticles were obtained by a precipitation process by mixing two solutions containing:
    (i) 0.1 M CaCl2 + 0.4 M Na3C6H5O7 and
    (ii) 0.12 M Na2HPO4 + 0.2M Na2CO3
    in proportion 1: 1 v / v, 200 ml in total and adjusting the pH to 8.5 with HCl at room temperature.
    When the mixture has a milky appearance (approximately 30 s after mixing), the particles undergo three successive cycles of sedimentation by centrifugation, removal of the supernatant and washing of the precipitate with ultrapure water (MilliQ ©, Millipore). Subsequently, the wet precipitate is lyophilized and the particles are subsequently characterized.
    To obtain these particles doped with F, 0.05 M CaF2 is added to the solution (ii).
    Characterization techniques
    The nanoparticles were analyzed with a Transmission Electron Microscope (STEM Philips CM 20) operated at 80 kV. This equipment also allowed to acquire the electron diffraction patterns of the nanoparticles as! such as X-ray energy dispersion spectra (EDS). For these observations, the lyophilized samples were dispersed in ultrapure water and then a few drops of this suspension were deposited on conventional copper racks.
    5
    10
    fifteen
    twenty
    25
    30
    35
    40
    Four. Five
    fifty
    The amount of Ca and P was quantified by optical emission spectroscope (ICP-OES) using a Liberty 200 spectrometer (Varian, Australia). For this, the lyophilized samples were dissolved in concentrated ultrapure nitric acid (1% v / v).
    The thermogravimetric analysis (TGA) was carried out with an SDT Q 600 system (TA Instruments, New Castle, DE, USA) under a constant flow of nitrogen (100 mL.min-1) and increasing the temperature to 1200 ° C in 10 ° C intervals. min-1.
    X-ray diffraction patterns were acquired with an X-Pert PRO diffractometer (PANalytical) equipped with a PIXcel detector operating at 45 kV and 40 mA, with Cu Ka incident radiation (A = 1.5418 A). Variable slits ("anti-scatter") were used, with an irradiation length of 10 mm. The range 20 was varied from 5 ° to 70 ° with increments 20 of 0.039.
    Raman spectra were obtained with a LabRAMHR spectrometer (Jobin-Yvon, Horiba, Japan). This equipment is provided with a diode laser as an excitation source (A = 532 nm), and a CCD detector cooled by Peltier (1026 x 256 pixels). The spectra were obtained with a spectral resolution of 3 cm -1.
    The amount of fluorine in the samples was quantified by X-ray fluorescence spectroscope (XRF) using a PHILIPS Magix Pro spectrometer (PW-2440). Additionally, the fluorine content was also determined by spectrophotometry by complexing it with zirconyl chloride and eriochrome cyanine R and measuring the absorbance of the complex at 570 nm.
    "In vitro" cell culture analysis
    The biological response of the nanoparticles was evaluated using human osteoblast cell lines (MG-63, Lonza, Italy). The cells were grown in DMEM / F12 medium (PAA, Austria), containing 10% fetal bovine serum (FBS) and penicillin-streptomycin (100 U / mL- 100pg / mL) at 37 ° C and in a CO2 atmosphere (5%). Subsequently, the cells were separated from their support by trypsinization and then centrifuged and resuspended. The Tripan blue exclusion test was used to count live cells (cell viability test). The cells were deposited in 96-well plates with a density of 3.0x103 cells per well. 24 hours later, three different concentrations of citrate-coated ACP nanoparticles (100 pg / mL, 500 pg / mL, 1000 pg / mL) previously sterilized by 25 kGy Y radiation were added to the cell culture. The incubation of the cells was performed under standard conditions (37 ° C, 5% CO2) for 1, 3 and 7 days. The culture medium was renewed every three days. All these tests were performed in a laminar flow cabinet.
    MTT cytotoxicity and cell viability assays
    The MTT method [3- (4,5-dimethylthiazol -2-yl) -2,5-diphenyltetrazolium bromide] was used to determine the possible toxic effect of the nanoparticles. This assay is based on the metabolic reduction of 3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazole (MTT) bromide by the mitochondrial enzyme succinate dehydrogenase in a blue colored compound (formazan) , whose concentration can be determined colorimetrically, allowing to determine the mitochondrial functionality of the treated cells.
    The cells, after being in contact with the nanoparticles for 1, 3 and 7 days, were incubated in MTT dissolved in PBS (5 mg / mL) at 1:10 for 2 hours at 37 ° C. The cells were then incubated with 200 pl of dimethylsulfoxide (Sigma) for 15 min to dissolve the formazan crystals. A Multiskan FC Microplate (Thermo Scientific) spectrophotometer was used to measure absorbance, which is directly proportional to the
    5
    10
    fifteen
    twenty
    25
    30
    number of metabolically active cells, at 570 nm. Three samples were analyzed for each of the times studied (1, 3 and 7 days).
    Results
    The electron microscope images (Fig. 1) indicate that both non-doped, ACP (A) and doped, FCAP (B) samples are spherical nanoparticles with sizes between 30 and 80 nm. In addition, the absence of diffraction points in the patterns reveals its amorphous character. In turn, the EDS spectra confirm that they are composed only of Ca and P. The peak of F in the spectrum of doped particles that should appear around 0.68 KeV is not observed because it is possibly overlapping with the oxygen peak (0.2 KeV), much more intense. The amorphous nature of the nanoparticles has been confirmed with dust diffraction patterns (Fig. 2A). The absence of peaks in diffraction patterns confirms the non-crystalline nature of these materials. Raman spectra are also typical of amorphous calcium phosphates since the main peak appears at 952 cm-1, slightly offset from the main peak of the hydroxyapatite (959 cm-1). The chemical composition of ACP and FACP materials obtained by TGA, ICP and X-ray fluorescence has already been described above.
    The biological response of the nanoparticles has been studied with osteoblast cells (MG-63). Three different concentrations of nanoparticles (100, 500 and 1000 pg / ml) were added to the culture medium and after a certain incubation period (1, 3 or 7 days) the number of metabolically active cells was quantified through MTT assays (Fig . 3). An increase in cell proliferation was observed in all cases (even for the highest concentration) after 1 to 7 days of incubation. In addition, for the lowest concentration studied, cell growth is comparable to that observed by cells in the absence of nanoparticles (control). However, with increasing concentration, cell growth is much less noticeable than in the control, possibly because they are excessively high nanoparticle concentrations. Despite this, the viability and cell morphology tests (not shown) gave very similar results for all the concentrations studied. These results clearly indicate that the nanoparticles are fully biocompatible in contact with this human osteoblast cell line.
    权利要求:
    Claims (11)
    [1]
    5
    10
    fifteen
    twenty
    25
    30
    35
    40
    Four. Five
    fifty
    1. - Method of obtaining amorphous calcium phosphate nanoparticles coated with citrate and fluorinated, comprising:
    - preparation of a solution of CaCl2 at a concentration between 0.08 M and 0.12 M and Na3C6H5O7 at a concentration between 0.35 M and 0.50 M
    - Preparation of a second solution formed by Na2HPO4 at a concentration between 0.10 M and 0.15 M with 0.2 M Na2CO3 and a fluorine compound.
    - mixing under agitation of the two solutions prepared in the previous stages in a proportion of 1: 1 v / v at pH between 8.3 and 8.7 at room temperature for a period of time less than 2 minutes.
    - three successive cycles of sedimentation by centrifugation, removal of the supernatant and washing of the precipitate with ultrapure water.
    - freeze drying of the wet precipitate.
    [2]
    2. - Method according to claim 1, characterized in that the concentrations of the reagents used for the first solution are 0.1 M for CaCl2 and 0.4 M for Na3C6H5O7.
    [3]
    3. - Method according to any one of claims 1 and 2, characterized in that the concentrations used for the second solution are 0.12 M for Na2HPO4 and 0.2 M for Na2CO3.
    [4]
    4. - Method according to any one of claims 1 to 3, characterized in that the fluorine compound is selected from CaF2, NaF and KF and added at a concentration between 0.01 M and 0.1 M.
    [5]
    5. - Method according to claim 4, characterized in that the fluorine compound is CaF2 which is added at a concentration of 0.05 M.
    [6]
    6. - Amorphous calcium-phosphate-coated calcium phosphate nanoparticles obtained by a method as defined in claims 1 to 5, characterized in that they have a spherical shape and size between 30 and 80 nm and Na, Ca contents. P, citrate, carbonate, fluoride and water between:
    - between 3.1% and 3.5% by weight of Na
    - between 27.0% and 27.4% by weight of Ca
    - between 37.0% and 37.8% by weight of P
    - between 3.5% and 5.0% by weight of citrate
    - between 5.4% and 7.0% by weight of carbonate
    - between 6.0% and 10.0% by weight of water
    - between 2.0% and 5.0% by weight of fluoride
    [7]
    7. Use of amorphous calcium phosphate nanoparticles coated with citrate and fluorinated, as defined in claim 6, as carriers of biomolecules, drugs or both.
    [8]
    8. - Use of amorphous calcium phosphate nanoparticles coated with citrate and fluorinated, as defined in claim 6, as biomaterials in orthopedic applications.
    [9]
    9. - Use of amorphous calcium phosphate nanoparticles coated with citrate and fluorinated, as defined in claim 6, for dental applications.
    [10]
    10. - Use according to claim 9, as a material for preparing cements for filling, sealing or both operations in root canals and dental repairs.
    [11]
    11. - Use according to claim 9, as a component of toothpastes, chewing gums, 5 mouthwashes, fluoride varnishes and gels to promote enamel remineralization
    by gradual release of calcium, phosphate and fluorine ions.
    类似技术:
    公开号 | 公开日 | 专利标题
    ES2557183B1|2016-11-03|Procedure for obtaining amorphous calcium phosphate nanoparticles coated with citrate and fluorinated
    Karlinsey et al.2010|Preparation, characterization and in vitro efficacy of an acid-modified β-TCP material for dental hard-tissue remineralization
    Combes et al.2010|Amorphous calcium phosphates: synthesis, properties and uses in biomaterials
    Yao et al.2009|Simultaneous incorporation of carbonate and fluoride in synthetic apatites: Effect on crystallographic and physico-chemical properties
    Rameshbabu et al.2006|Synthesis of nanocrystalline fluorinated hydroxyapatite by microwave processing and its in vitro dissolution study
    US7670579B2|2010-03-02|Nanostructured bioactive materials prepared by dual nozzle spray drying techniques
    AU2008248087B2|2013-03-28|Hybrid organic/inorganic chemical hybrid systems, including functionalized calcium phosphate hybrid systems, and a solid-state method of producing the same
    Marques et al.2017|Biocompatibility and antimicrobial activity of biphasic calcium phosphate powders doped with metal ions for regenerative medicine
    ES2709828T3|2019-04-17|Hollow particles of calcium phosphate
    Cheng et al.2010|Effect of compounds of Galla chinensis on remineralization of enamel surface in vitro
    Zaharia et al.2017|Biomimetic chitosan-hydroxyapatite hybrid biocoatings for enamel remineralization
    De Caluwé et al.2016|Bioactivity and biocompatibility of two fluoride containing bioactive glasses for dental applications
    Zhang et al.2014|Tailoring Si-substitution level of Si-hydroxyapatite nanowires via regulating Si-content of calcium silicates as hydrothermal precursors
    Hua et al.2020|In vitro remineralization of enamel white spot lesions with a carrier-based amorphous calcium phosphate delivery system
    CN107735070B|2021-04-23|Powder for forming tooth surface film comprising calcined apatite
    ES2542990T3|2015-08-13|Dental material that forms hydroxylapatite with bioactive action
    Dorozhkin2014|Calcium orthophosphates: Occurrence, properties and major applications
    Balhuc et al.2021|Dental Applications of Systems Based on Hydroxyapatite Nanoparticles—An Evidence-Based Update
    KR20210025624A|2021-03-09|Stabilized amorphous calcium carbonate doped with fluorine ions and method for producing same
    Nazemi et al.2014|Synthesis, characterisation and antibacterial effects of sol-gel derived biphasic calcium phosphate nanopowders
    Karimi et al.2018|In vitro biodegradability–bioactivity–biocompatibility and antibacterial properties of SrF2 nanoparticles synthesized by one-pot and eco-friendly method based on ternary strontium chloride-choline chloride-water deep eutectic system
    Kazuz et al.2020|α-Tricalcium phosphate/fluorapatite based composite cements: Synthesis, mechanical properties, and biocompatibility
    CN108785106B|2021-03-16|Colloidal silver-containing calcium phosphate nanocomposite and preparation method and application thereof
    Zalite et al.2016|Characterization of different hydroxyapatite particles for tooth enamel remineralization
    ATSUSHI et al.2018|Study of a method to prepare novel carbonate-containing apatite porous bodies
    同族专利:
    公开号 | 公开日
    WO2016012452A1|2016-01-28|
    EP3177273B1|2019-03-20|
    RU2017101869A3|2019-01-30|
    ES2731048T3|2019-11-13|
    US20170209491A1|2017-07-27|
    KR20170052572A|2017-05-12|
    EP3177273A1|2017-06-14|
    RU2692309C2|2019-06-24|
    ES2557183B1|2016-11-03|
    JP6564457B2|2019-08-21|
    BR112017001426A2|2017-11-28|
    JP2017522385A|2017-08-10|
    US10105390B2|2018-10-23|
    CN106999355B|2020-02-04|
    RU2017101869A|2018-08-21|
    PT3177273T|2019-07-08|
    CN106999355A|2017-08-01|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    CA2174244A1|1993-11-01|1995-05-11|Nir Kossovsky|Biochemically active agents for chemical catalysis and cell receptor activation|
    AUPO566297A0|1997-03-13|1997-04-10|University Of Melbourne, The|Calcium phosphopeptide complexes|
    DE60013773T2|1999-02-03|2005-11-10|Biosante Pharmaceuticals, Inc.|Methods for the preparation of therapeutic calcium phosphate particles|
    JP2001169121A|1999-12-08|2001-06-22|Ricoh Co Ltd|Facsimile machine|
    CA2469431C|2002-01-03|2009-05-26|The Procter & Gamble Company|Stable oral compositions comprising casein phosphopeptide complexes and fluoride|
    US7351280B2|2004-02-10|2008-04-01|New York University|Macroporous, resorbable and injectible calcium phosphate-based cements for bone repair, augmentation, regeneration, and osteoporosis treatment|
    US7670579B2|2004-04-06|2010-03-02|American Dental Association Foundation|Nanostructured bioactive materials prepared by dual nozzle spray drying techniques|
    RU2391119C1|2008-10-09|2010-06-10|Федеральное агентство по науке и инновациям|Method of obtaining calcium phasphte nanoparticles, stabilised by salt matrix|
    CN101428779A|2008-12-05|2009-05-13|江苏大学|Hollow nanostructured hydroxyapatite and method for producing the same|AU2015370986B2|2014-12-22|2021-02-04|Consiglio Nazionale Delle Ricerche|Products for the delivery of therapeutic/diagnostic compounds to the heart|
    IT201800006753A1|2018-06-28|2019-12-28|STABILIZED AMORPHOUS CALCIUM PHOSPHATE DOPED WITH FLUORIDE IONS AND A PROCEDURE FOR PRODUCING IT|
    CN110251733A|2019-07-17|2019-09-20|成都理工大学|High active unformed calcium phosphate/calcium citrate composite granule of biomineralization and preparation method thereof|
    ES2879098A1|2020-05-18|2021-11-19|Univ Granada|Ethanolic extract of Euphorbia lathyris seeds, method to obtain it, pharmaceutical composition that contains it and its use as an antitumor agent |
    法律状态:
    2016-11-03| FG2A| Definitive protection|Ref document number: 2557183 Country of ref document: ES Kind code of ref document: B1 Effective date: 20161103 |
    2021-12-03| FD2A| Announcement of lapse in spain|Effective date: 20211203 |
    优先权:
    申请号 | 申请日 | 专利标题
    ES201431091A|ES2557183B1|2014-07-21|2014-07-21|Procedure for obtaining amorphous calcium phosphate nanoparticles coated with citrate and fluorinated|ES201431091A| ES2557183B1|2014-07-21|2014-07-21|Procedure for obtaining amorphous calcium phosphate nanoparticles coated with citrate and fluorinated|
    ES15748187T| ES2731048T3|2014-07-21|2015-07-21|Procedure for obtaining amorphous calcium citrate coated phosphorus calcium phosphate nanoparticles|
    KR1020177004687A| KR20170052572A|2014-07-21|2015-07-21|Process for obtaining fluoride-doped citrate-coated amorphous calcium phosphate nanoparticles|
    PCT/EP2015/066651| WO2016012452A1|2014-07-21|2015-07-21|Process for obtaining fluoride-doped citrate-coated amorphous calcium phosphate nanoparticles|
    PT15748187T| PT3177273T|2014-07-21|2015-07-21|Process for obtaining fluoride-doped citrate-coated amorphous calcium phosphate nanoparticles|
    RU2017101869A| RU2692309C2|2014-07-21|2015-07-21|Method of producing amorphous calcium phosphate nanoparticles coated with citrate and doped with fluoride|
    EP15748187.0A| EP3177273B1|2014-07-21|2015-07-21|Process for obtaining fluoride-doped citrate-coated amorphous calcium phosphate nanoparticles|
    CN201580050650.XA| CN106999355B|2014-07-21|2015-07-21|Method for obtaining fluoride doped citrate coated amorphous calcium phosphate nanoparticles|
    US15/327,817| US10105390B2|2014-07-21|2015-07-21|Process for obtaining fluoride-doped citrate-coated amorphous calcium phosphate nanoparticles|
    JP2017524101A| JP6564457B2|2014-07-21|2015-07-21|Process for obtaining amorphous calcium phosphate nanoparticles doped with fluoride and coated with citrate|
    BR112017001426A| BR112017001426A2|2014-07-21|2015-07-21|process for obtaining fluoride-doped citrate amorphous calcium phosphate nanoparticles|
    [返回顶部]